Unlock Exclusive Discounts & Flash Sales! Click Here to Join the Deals on Every Wednesday!
Antibody–drug conjugates (ADC) are one of the fastest growing anticancer drugs. This approach comprises a mAb conjugated to the cytotoxic payload via a chemical linker that directed toward a target antigen expressed on the cancer cell surface, reducing systemic exposure and therefore toxicity. The mAb component of the ADC enables it to circulate in the bloodstream until it finds and binds to tumour-specific (or tumour-associated) cell surface antigens present on target cancer cells.